Navigation Links
Cancer Advances Announces Allowance of a New Patent to Its Suite of Gastrin Inhibitor Products
Date:7/15/2013

Durham, North Carolina (PRWEB) July 15, 2013

Cancer Advances, Inc. (Cancer Advances), a wholly owned, biotechnology portfolio company of Cato BioVentures, announces the allowance of a new patent. The newly released patent covers monoclonal antibodies to the gastrin hormone and has been allowed in Canada. This patent is an additive to Cancer Advances’ suite of products that work to inhibit the cancer promoting hormone, gastrin.

Cancer Advances has developed an intellectual property portfolio that currently holds over 100 United States and worldwide patents related to a lead compound, Polyclonal Antibody Stimulator (PAS) that has been clinically studied in three gastrointestinal cancers. PAS is an active immunotherapeutic that induces antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, of which there is extensive published evidence for a central role of both of these endogenous compounds in the development and progression of gastrointestinal tumors, as well as other tumors.

The monoclonal antibodies to gastrin hormone patent cover a pharmaceutical composition, comprised of a humanized monoclonal antibody to gastrin. This patent also covers a method of diagnosing, preventing or treating a gastrin-mediated disease or condition. Combined with Cancer Advances’ already extensive arsenal of patents, this newly allowed patent will help in the fight against gastrin-mediated diseases.

For more information, please contact:
Lynda Sutton
President, Cancer Advances
lsutton(at)cato(dot)com
919-361-2162
http://www.canceradvancesinc.com

About Cancer Advances <
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
4. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Progyny, Inc., the new ... announced that it has secured additional capital from investors ... SR One and Merck Serono Ventures. The funding will ... the best fertility outcomes by aligning science, technology, clinics ... marketplace for families seeking fertility solutions and we are ...
(Date:4/21/2015)... YourEncore, an Indianapolis, Indiana-based company that ... and food sciences industries solve complex development, regulatory ... Research Excellence and Safety (ACRES), a Massachusetts-based non-profit ... have partnered to speed innovation in the medical ... to ACRES experts with proven experience, tools, and ...
(Date:4/20/2015)... Texas , April 20, 2015 ... surgeons for healing bone injuries. The orthobiologics market is ... opportunities for its stakeholders. The global orthobiologics market report ... forecast of revenue. The global orthobiologics market was valued ... reach $7,900.2 million by 2019, at a CAGR of ...
(Date:4/20/2015)... 2015  "Everybody is affected by cancer sooner or ... frankly brutal. We,ve got to get away from that."  ... witnessed a loved one or friend battling for their ... chemotherapy and other treatments cause the human body. It,s ... up and succumb to the disease. Dr. Dionne has ...
Breaking Biology Technology:Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2
... Soyfoods Even HealthierST. LOUIS, March 31 Recent research ... to be beneficial to the diet. And, the majority ... products such as soyfoods even healthier. These findings come ... Survey - sponsored by the United Soybean Board ...
... 30 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... products, today announced its financial results for the fourth ... are very happy to report that our partner Auxilium ... enrollment in a Phase IIb trial in Peyronie,s disease ...
... 30 Mylan Inc. (Nasdaq: MYL ) ... in which it holds a 71.2% controlling interest, has ... and Drug Administration (FDA) under the President,s Emergency Plan ... Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, ...
Cached Biology Technology:Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 7Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R) 2
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... with a number of pathological conditions, including cancer. Publishing in ... in drinking water given at the maximum levels permitted ... in mice. On the other hand, reducing copper levels reduced ... essential factor for the growth of tumors in humans as ...
... Hall Institute have been awarded more than $2.2 million from ... disorders and inflammatory diseases. Three institute researchers - ... - were announced last week as recipients of ARC Future ... body controls errant immune cells that cause type 1 diabetes ...
... , Nov. 14, 2013  Based on its recent research ... presents Cognitec Systems GmbH with the 2013 European ... Cognitec,s blinkers-on focus on face biometrics earned the ... to develop its flagship face recognition technology, FaceVACS-VideoScan. ...
Cached Biology News:Copper intake makes tumors breathe 2ARC Future Fellows awarded $2.2M for immune and inflammation studies 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 3Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 4Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 5
... I (RNase-free) (E.C. 3.1.21.1) is a nonspecific ... chromatin. It functions by hydrolyzing phosphodiester linkages, ... and a 3'-hydroxyl group. Ambion's RNase-free DNase ... and is recommended to degrade DNA in ...
hnRNP U (H-94)...
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
... is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us ... up,and market it internationally. We work under ...
Biology Products: